Cargando…

Cost of three models of care for drug-resistant tuberculosis patients in Nigeria

BACKGROUND: Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bada, Florence O., Okpokoro, Evaezi, Blok, Nick, Meribole, Emmanuel, Dutt, Saswata, Dakum, Patrick, Abimiku, Alash’le, Zwerling, Alice, Kik, Sandra V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327521/
https://www.ncbi.nlm.nih.gov/pubmed/30630429
http://dx.doi.org/10.1186/s12879-018-3636-1
_version_ 1783386484676493312
author Bada, Florence O.
Okpokoro, Evaezi
Blok, Nick
Meribole, Emmanuel
Dutt, Saswata
Dakum, Patrick
Abimiku, Alash’le
Zwerling, Alice
Kik, Sandra V.
author_facet Bada, Florence O.
Okpokoro, Evaezi
Blok, Nick
Meribole, Emmanuel
Dutt, Saswata
Dakum, Patrick
Abimiku, Alash’le
Zwerling, Alice
Kik, Sandra V.
author_sort Bada, Florence O.
collection PubMed
description BACKGROUND: Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is required to guide the scale up of DR-TB care. We aimed to estimate and compare the costs of different DR-TB treatment and care models in Nigeria. METHODS: We estimated the costs associated with three models of DR-TB treatment and care: Model (A) patients are hospitalized throughout the 8-month intensive phase, Model (B) patients are partially hospitalized during the intensive phase and Model (C) is entirely ambulatory. Costs of treatment, in-patient and outpatient care and diagnostic and monitoring tests were collected using a standardized data collection sheet from six sites through an ingredient’s approach and cost models were based on the Nigerian National Tuberculosis, Leprosy and Buruli Ulcer Guideline - Sixth Edition (2014) and Guideline for programmatic and clinical management of drug-resistant tuberculosis in Nigeria (2015). RESULTS: Assuming adherence to the Nigerian DR-TB guidelines, the per patient cost of Model A was $18,528 USD, Model B $15,159 USD and Model C $9425 USD. Major drivers of cost included hospitalization (Models A and B) and costs of out-patient consultations and supervision (Model C). CONCLUSION: Utilizing a decentralized ambulatory model, is a more economically viable approach for the expansion of DR-TB care in Nigeria, given that patient beds for DR-TB treatment and care are limited and costs of hospitalized treatment are considerably more expensive than ambulatory models. Scale-up of less expensive ambulatory care models should be carefully considered in particular, when treatment efficacy is demonstrated to be similar across the different models to allow for patients not requiring hospitalization to be cared for in the least expensive way.
format Online
Article
Text
id pubmed-6327521
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63275212019-01-15 Cost of three models of care for drug-resistant tuberculosis patients in Nigeria Bada, Florence O. Okpokoro, Evaezi Blok, Nick Meribole, Emmanuel Dutt, Saswata Dakum, Patrick Abimiku, Alash’le Zwerling, Alice Kik, Sandra V. BMC Infect Dis Research Article BACKGROUND: Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is required to guide the scale up of DR-TB care. We aimed to estimate and compare the costs of different DR-TB treatment and care models in Nigeria. METHODS: We estimated the costs associated with three models of DR-TB treatment and care: Model (A) patients are hospitalized throughout the 8-month intensive phase, Model (B) patients are partially hospitalized during the intensive phase and Model (C) is entirely ambulatory. Costs of treatment, in-patient and outpatient care and diagnostic and monitoring tests were collected using a standardized data collection sheet from six sites through an ingredient’s approach and cost models were based on the Nigerian National Tuberculosis, Leprosy and Buruli Ulcer Guideline - Sixth Edition (2014) and Guideline for programmatic and clinical management of drug-resistant tuberculosis in Nigeria (2015). RESULTS: Assuming adherence to the Nigerian DR-TB guidelines, the per patient cost of Model A was $18,528 USD, Model B $15,159 USD and Model C $9425 USD. Major drivers of cost included hospitalization (Models A and B) and costs of out-patient consultations and supervision (Model C). CONCLUSION: Utilizing a decentralized ambulatory model, is a more economically viable approach for the expansion of DR-TB care in Nigeria, given that patient beds for DR-TB treatment and care are limited and costs of hospitalized treatment are considerably more expensive than ambulatory models. Scale-up of less expensive ambulatory care models should be carefully considered in particular, when treatment efficacy is demonstrated to be similar across the different models to allow for patients not requiring hospitalization to be cared for in the least expensive way. BioMed Central 2019-01-10 /pmc/articles/PMC6327521/ /pubmed/30630429 http://dx.doi.org/10.1186/s12879-018-3636-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bada, Florence O.
Okpokoro, Evaezi
Blok, Nick
Meribole, Emmanuel
Dutt, Saswata
Dakum, Patrick
Abimiku, Alash’le
Zwerling, Alice
Kik, Sandra V.
Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
title Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
title_full Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
title_fullStr Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
title_full_unstemmed Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
title_short Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
title_sort cost of three models of care for drug-resistant tuberculosis patients in nigeria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327521/
https://www.ncbi.nlm.nih.gov/pubmed/30630429
http://dx.doi.org/10.1186/s12879-018-3636-1
work_keys_str_mv AT badaflorenceo costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT okpokoroevaezi costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT bloknick costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT meriboleemmanuel costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT duttsaswata costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT dakumpatrick costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT abimikualashle costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT zwerlingalice costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria
AT kiksandrav costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria